Immunotherapy associated with improved survival for patients with melanoma brain metastases

(American Association for Cancer Research) Among patients with cutaneous melanoma who had brain metastases (MBM), first-line treatment with a checkpoint inhibitor was associated with a 1.4-fold increase in median overall survival, according to results from a national cohort.